Coherent Market Insights has announced new analysis on Cell Therapy Manufacturing Market Status 2021-2027 which has been prepared based on an in-depth market analysis with inputs from industry experts and top vendors in the business. The report covers the market landscape and its development prospects over the coming years. The report also contains a discussion of the key vendors operating in this market.

Request Here For PDF Brochure

Cell therapy is a very effective medicinal procedure, where human cells are injected for restoration of damaged tissue. Cell theory repairs the damaged tissues of an organ rather than producing new organ. With the use new technologies and innovation, cell therapies have gained significant traction and are recognised for potentially treating the wide range of diseases such as immune deficiency, tissue degradation and metabolic disorders. The therapy is classified into two different types. The first one is allogeneic that is cells from third party donor and the second one autologous that is cells from ones own body. The main objective of cell therapy implication is to restore the damaged cells of an organ and allow the similar functioning of damaged tissues as earlier.

Some of the clinical trials of cell therapies were established and permitted. For instance, in 2013, a stage 2 clinical trial for bone marrow transplantation was performed by rheumatoid arthritis deriving stem cells in affected knee. This technique was grown due to collaboration of the government agencies. According to the U.K. 2014 report, government funded US$15.3 million in cell therapy manufacturing market.

Market Drivers:-

The increase in number of chronic diseases would lead to growth of the cell therapy manufacturing market as many such diseases are getting treated by cell therapy. New medications are implanted and regenerative medicine is also highly adopted leading to market growth. Stem cells transplantation is one of the effective medical therapy that treats certain advance stage diseases like diabetes, cancer, arthritis, blindness, cerebral palsy, Alzheimers, autism, etc. For instance, in 2015, World Health Organization (WHO) reported the annual worldwide stem cell transplants reach up to more than 50,000 transplants in various surgeries. The new medical therapy is demanded due to increasing number of trauma and accidents leading to increasing number of surgical procedures across the world. Some of the major biopharmaceutical companies are invested in research for cell therapy. For instance, in 2018, a biopharmaceutical company named as Longeveron LL, received a grant of US$ 750,000 for stem cell therapy research from the Maryland Technology Development Corporation (TEDCO). These government funding and collaborations among companies boosts the cell therapy manufacturing market growth.

Market Opportunities:-

The adoption of cell therapy is increasing in the developing countries. As cell therapy is one of the effective methods to treat certain chronic diseases even at the advanced stage, various developing regions are adopting the method of cell therapy. This gives various opportunities for players in the cell therapy manufacturing market.

Market Restraints:-

The key factor that is declining growth of the cell therapy manufacturing market is high manufacturing cost of cell therapy. As it is not cost effective, patients tends to move towards another option restraining market growth. Moreover, the strict guidelines and regulations, as well as diverse health safety concerns over cell therapy treatment are declining the cell therapy manufacturing market growth.

Regional Analysis:-

The global cell therapy manufacturing market is segmented into North America, Latin America, Asia Pacific, Europe, Africa and Middle East. Among everyone, North America owes largest number of performed surgeries and holds the dominant position in the global cell therapy manufacturing market. North America is also developed in technologically advanced products for therapy. The Centres for Disease Control & Prevention (CDC) provided the National Health Statistics Report that states, US performed around 201,748.3 million non-surgical and surgical procedures in 2011.

Moreover, Asia Pacific is also expected to have a significant growth in the global cell therapy manufacturing market in the near future. Local players in the market would grab marginal market share due to growing patients of various chronic and infectious diseases such as cancer, HIV, hepatitis etc. and less stringent regulatory requirements. Therefore, cell therapy could be at the marginal low cost that would provide better solutions to the patients.

Key Players:-

The key players operating the global cell therapy manufacturing market are Gene Therapy Catapult EUFETS, Pharmicell, CELLforCURE Merck Group, MaSTherCell, Thermo Fisher, Dickinson and Company, Miltenyi Biotec GmBH, MEDIPOST, Cognate BioServices, PharmaCell, Lonza Group, STEMCELL Technologies, Holostem Terapie Avanazate, Bio-Rad Laboratories, Inc., Takara Bio Group, Pluristem Therapeutics, Cellular Dynamics International, Anterogen, Becton, Brammer Bio, Osiris Therapeutics, and WuXi AppTec.

Some of the key players are adopting growth strategies such as introduction of new technologies and devices to keep up the top position in the market. For instance, for treating type 1 diabetes ViaCyte, Inc. successfully implanted VC-01 an embryonic stem cell derived islet in 2014.

Buy instant copy of this research report with Flat US $ 2000 Off@ https://www.coherentmarketinsights.com/promo/buynow/1728

Main points in Cell Therapy Manufacturing Market Report Table of Content

Chapter 1 Industry Overview1.1 Definition1.2 Assumptions1.3 Research Scope1.4 Market Analysis by Regions1.5 Cell Therapy Manufacturing Market Size Analysis from 2021 to 202711.6 COVID-19 Outbreak: Cell Therapy Manufacturing Industry Impact

Chapter 2 Global Cell Therapy Manufacturing Competition by Types, Applications, and Top Regions and Countries2.1 Global Cell Therapy Manufacturing (Volume and Value) by Type2.3 Global Cell Therapy Manufacturing (Volume and Value) by Regions

Chapter 3 Production Market Analysis3.1 Global Production Market Analysis3.2 Regional Production Market Analysis

Chapter 4 Global Cell Therapy Manufacturing Sales, Consumption, Export, Import by Regions (2016-2021)Chapter 5 North America Cell Therapy Manufacturing Market AnalysisChapter 6 East Asia Cell Therapy Manufacturing Market AnalysisChapter 7 Europe Cell Therapy Manufacturing Market AnalysisChapter 8 South Asia Cell Therapy Manufacturing Market AnalysisChapter 9 Southeast Asia Cell Therapy Manufacturing Market AnalysisChapter 10 Middle East Cell Therapy Manufacturing Market AnalysisChapter 11 Africa Cell Therapy Manufacturing Market AnalysisChapter 12 Oceania Cell Therapy Manufacturing Market AnalysisChapter 13 South America Cell Therapy Manufacturing Market AnalysisChapter 14 Company Profiles and Key Figures in Cell Therapy Manufacturing BusinessChapter 15 Global Cell Therapy Manufacturing Market Forecast (2021-2027)Chapter 16 ConclusionsResearch Methodology

Request for a Sample Report

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. ShahCoherent Market Insights1001 4th Ave, #3200Seattle, WA 98154Phone: US +12067016702 / UK +4402081334027Email: sales@coherentmarketinsights.com

View original post here:

Cell Therapy Manufacturing Market | Exclusive Report on the Latest Market Trends and Development - PharmiWeb.com

The National Comprehensive Cancer Network (NCCN) has announced a significant update to the guidelines for COVID-19 vaccine administration, including a third dose, in patients with cancer, according to a press release issued by the organization.1

The recommendation indicated that several groups of individuals should be eligible for a third dose of the COVID-19 vaccine, including those with new or recurring solid tumors within 1 year of their initial vaccine dose regardless of therapy, as well as those with active hematologic malignancies. Patients who have received a stem cell transplant (SCT) or engineered cellular therapy such as CAR T-cell therapy within the past 2 years should also eligible, as well as those who are recipients of SCT on immunosuppressive therapy or with a history of graft-versus-host disease regardless of when the transplant took place.

COVID-19 can be very dangerous, especially for people living with cancer, which is why were so grateful for safe and effective vaccines that are saving lives, Robert W. Carlson, MD, chief executive officer of the NCCN, said in a press release. Our organization exists to improve the lives of people with cancer; we have a long track record for making recommendations that improve quality and length of life. We want our patients to live the longest and best lives possible, which means following the science on vaccination and mask-wearing.

The NCCN COVID-19 Vaccine Advisory Committee consists of multidisciplinary physicians across the NCCNs Member Institutions. In particular, the committee includes experts in infectious diseases, vaccine development and delivery, cancer management, and medical ethics. The recommendations, which are based on available evidence and expert consensus, have been utilized globally to aid in making management decisions over the course of the COVID-19 pandemic.

When it comes to peoples safety, we have to take every precaution, Steve Pergam, MD,

MPH, associate professor of the Vaccine and Infectious Disease Division at Fred Hutchinson

Cancer Research Center and infection prevention director at Seattle Cancer Care Alliance, as well as the co-leader of the NCCN COVID-19 Vaccination Advisory Committee, said in a press release. That means even after a third dose of vaccine, we still recommend immunocompromised peoplesuch as those undergoing cancer treatmentcontinue to be cautious, wear masks, and avoid large group gatherings, particularly around those who are unvaccinated. All of us should do our part to reduce the spread of COVID-19 and get vaccinated to protect those around us from preventable suffering.

Additional recommendations from the updated guidelines suggest that all eligible caregivers and close contacts of those with cancer should be immunized whenever possible.2 The use of all vaccines with FDA approval or emergency use authorizationincluding the Pfizer/BioNTech BNT162b2 mRNA vaccine (Comirnaty), the Moderna mRNA-1273 SARS-CoV-2 vaccine, and the Janssen Ad26.COV2.S Adenovirus vector vaccineis recommended in eligible patients by the committee.

Those who are receiving allogeneic or autologous SCT or CAR T-cell therapy will need to wait at least 3 months post-therapy before receiving the vaccine. Patients with hematologic malignancies, including those receiving cytotoxic chemotherapy such as cytarabine and anthracycline-based induction regimens for acute myeloid leukemia, need to delay inoculation until absolute neutrophil count recovery. Those who are experiencing marrow failure from their disease and/or are expected to have limited or no recovery from their therapy as well as those who are receiving long-term maintenance are able to receive the vaccine once it is available.

In solid tumors, the vaccine may be received once available for those who are undergoing treatment with cytotoxic chemotherapy, targeted therapy, checkpoint inhibitors, and other immunotherapy or radiation therapy. Those who are undergoing major surgery need to wait a few days following their surgical procedure before getting the vaccines.

The Center for Disease Control (CDC) currently recommends a third dose of the mRNA COVID-19 vaccines for individuals who are moderately to severely immunocompromised. This includes:

The CDC recommends that a third dose of the mRNA COVID-19 vaccine should be given at a minimum of 4 weeks following the second dose of either the Moderna or Pfizer vaccines. Notably, although preliminary data indicate that a third dose could augment antibody titers in an immunocompromised population of patients, those who have been diagnosed with cancer continue to be at a higher risk for infection with COVID-19 and COVID-19related complications. Even with the additional dose, infection is still possible meaning that precautions such as avoiding crowds and wearing a mask are recommended.

Read the original here:

NCCN Issues Updated Guidelines Regarding Third COVID-19 Vaccine Booster for Those With Cancer - Cancer Network

A jury awarded a North Texas physician $7.8 million after finding his business partner locked him out of their jointly owned stem cell therapy clinic in 2018.

Wade McKenna, an orthopedic surgeon and CEO of McKenna Orthopedics and Biologics, sued his former partner Neil Riordan for conspiring to ax him from his ownership stake in the Southlake-based Riordan-McKenna Institute and transfer the companys assets to another clinic Riordan owned.

Riordan, a scientist specializing in stem-cell research, ran the Riordan Medical Institute at the same location as the Riordan-McKenna Institute following the schism, using the same initials as the original clinic.

Jurors in a Tarrant County District Court found that McKenna wasnt fairly compensated for the assets transferred to the Riordan Medical Institute or for the revenue generated at the competing business.

You see business splits quite a bit, but usually not something this egregious, said Derrick Boyd, McKennas lead trial lawyer from Boyd Powers & Williamson.

Riordan said he was disappointed in the decision and would be pursuing post-trial options.

We disagree mightily with the result in the trial and plan to present appropriate post-trial motions to the court and, if necessary, to appeal this unjust ruling result to the court of appeals, Riordan said.

McKennas dismissal from the Riordan-McKenna Institute caught the doctor off guard, Boyd said. On May 16, 2018, Riordans lawyer delivered McKenna a letter stating that Riordan wished to sever their business partnership.

The current board, which consists of Dr. Riordan and David Murfin, has determined that it is in the best interest of RMI to terminate your affiliation with RMI in all regards including, but not limited to, your role as medical director, the letter said. As such, Dr. Riordan requests that you turn in your keys to the RMI office.

The letter gave two options for the future of the company: a dissolution or a buyout. Under the buyout, Riordan offered to buy McKennas 45% stake in the company for $500,000.

Boyd said McKenna was denied access to company financial records when he questioned the suggested buyout compensation, inspiring McKenna to sue his former partner.

In the lawsuit that was decided Aug. 31, jurors said Riordan failed to comply with his fiduciary duty to the company and that McKenna, as a member of the institute, had a right to assert such a claim.

Under the decision, McKenna was awarded damages for his stake in the company, improper financial distributions to Riordan-owned entities and a 45% share of amounts improperly received by Riordan or Riordan-owned entities from operations at RMI after May 16, 2018.

The verdict also included $5 million in punitive damages, Boyd said.

Go here to read the rest:

Jury awards North Texas doctor $7.8 million in lawsuit over his partner locking him out - The Dallas Morning News

The theory is currently being investigated in the phase 3 SIERRA trial (NCT02665065) of the radio immunotherapy Iomab-B versus the standard of care (SOC). Preliminary safety data from the study showed that myeloablative conditioning with Iomab-Bled to lower rates of severe mucositis, febrile neutropenia, and sepsis compared with SOC, even though radiation was administered at a high dose. The early findings suggest that use of myeloablative conditioning with Iomab-Bmay be beneficial to elderly patients with relapsed/refractory AML prior to hematopoietic stem cell transplantation.

One-hundred fifty patients will be enrolled in the study, and preliminary safety results were available for 54. The cohort received a median dose of 636 mCi (range, 354-1027 mCi)of Iomab-B. The median dose of radiation to the marrow in the Iomab-B group was 4.9 Gy (range, 4.6-32 Gy)and to the GI tract was 2.8 Gy to GI tract.

In an interview with Targeted Oncology, Rajneesh Nath, MD, director of Stem Cell Transplant at Banner MD Anderson, discussed the need for novel treatment for elderly patients with relapsed/refractory AML and how the SIERRA trial is designed to help.

TARGETED ONCOLOGY: What are outcomes like for patients who cannot tolerate transplant. What was additionally done to help these patients in your study?

Nath: Acute myeloid leukemia is the disease of the elderly. The median age at diagnosis is about 68 years and it's continuing to increase 1 to 2 years. Traditionally, and in different database, we saw that as the patients get older with the diagnosis of AML, they don't tend to do well with whatever treatment we throw at them. And 1 to 2 years survival is of the order of 10% or less. Traditionally, these patients will get an induction chemotherapy, if they can tolerate it. If they go into complete remission, patients who would be eligible for as allogeneic stem cell transplant. There are a lot of beliefs about the elderly patients, most hematologists in have a set cutoff age for after which they will not refer patients to a transplant, but this is not the case anymore. There's several studies that have shown that older patients who undergo allergenic stem cell transplant are able to do equally as well as some of the younger patients.

What was the hypothesis targeted delivery of Iomab-B to the marrow in patients with relapsed/refractory AML?

Generally speaking, there are 2 kinds of transplant myeloablative and reduced intensity. Myeloablation goes with increased intensity of chemotherapy and higher doses of radiation. What happens is this increase intensity increases toxicity. With targeted Myeloablation, what we are doing is delivering radiation where it is needed, and that is to the bone marrow. So, what we are able to do is target radiation to the sites where there is leukemia, and at the same time, save the critical orders that include heart, lungs, kidneys.

In the particular study, what we show is that while we are able to deliver myeloablative doses of chemotherapy to the bone marrow, we can spare the GI tract, which means that there will be less mucositis and GI toxicity which will translate to a decrease in neutropenic fever and sepsis.

Can you provide an overview of the study?

This was an interim analysis of the SIERRA trial of Iomab-B in elderly relapsed/refractory patients with AML. The way that trial worked was if you are over the age of 55, and have a relapsed or refractory acute myelogenous leukemia, and you have a fully matched donor. These patients are randomized one to one either to the Iomab-B, which is the experimental arm or the standard of care arm. If they go to the Iomab-B, they get a transplant, even though they have an active disease at the time. If they go into remission, we look at what is the duration of remission, and the primary end point of the trial is 6-month duration of remission.

In that case that they are randomized to the standard of care, they can get whatever chemotherapy of the choosing of the treating oncologist, if they go into remission after receiving that chemotherapy, they can get a standard stem cell transplant or the treating physicians oncologist team, or if they do not go into remission, they can be crossed over to the Iomab-B arm. What we looked at was the toxicity in these 2 groups of patients.

What were the result of this study?

Only about 4% of the patients in Iomab-B arm had sepsis. This was in contrast to 13% of the patients who receive standard of care treatment. Also, with Iomab-B, we saw 40% neutropenic fever, which would be expected, and less than 10% of the patients had grade 3 or 4 mucositis.

What is next for this study?

Only 75% of the land enrollment is a complete. We expect to complete the study this year when total of 150 patients will be randomized. And the next million-dollar question is we have shown in several of the interim analyses that the procedure is safer and is not toxic. The next real question is, is this effective as compared to the standard of care treatment? Once the analysis is complete, we'll know the answer to that.

As this treatment strategy moves forward in clinical trial development, what is your vision for its future use in this patient population? Are there any other exciting strategies emerging for the older subgroup?

It's an exciting time to be treating elderly patients with acute myeloid leukemia. Until a couple of years ago, we didn't have anything for them, we would just see which patients would be eligible for induction which many of these patients were not. We recently had several new approvals for this disease.

One of the particular areas that I'm excited about is the use of combination of hypomethylating agents with venetoclax [Venclexta]. This combination is able to free a lot of elderly patients and put them into remission. It serves as a pathway to take them to stem cell transplant because the outcomes of stem cell transplant are better if they are done in remission. So, on one hand, we are able to put an increasing number of patients into remission and provide them a pathway for stem cell transplant. On the other hand, if this study works out, we will be having a pathway for patients who do not go into remission, also to proceed with an allergenic stem cell transplant.

In your opinion, what promise does myeloablative targeted conditioninghave for the future?

This technology, while initially may be approved for acute myeloid leukemia in the elderly, may have role in several other clinical situations, like patients who have comorbidities and are not able to get full intensity chemotherapy. We can also use this technology in patients who go into transplant with minimal residual disease, though these patients may be technically considered in remission. Because they have small amount of disease, they do not do as well as those patients who are transplanted who are in an MRD-negative state. So, it will open up a lot more areas where we can consider using this technology.

Reference:

Nath R, Choe H, Stiff P, et al.Myeloablative Targeted conditioning with anti-cd45 iodine (131I) apamistamab [Iomab-b] spares the GI tract and has low incidence of severe mucositis, febrile neutropenia and sepsis in the prospective, randomized phase 3 SIERRA trial for patients with relapsed or refractory acute myeloid leukemia (AML). Presented at: 2021 Transplantation & Cellular Therapy Meetings; February 8-12, 2021; Virtual. Abstract 59.

The rest is here:

Iomab-B Shows Early Promise Versus Standard Therapy in Elderly R/R AML - Targeted Oncology

Patent Issued Grants Protection for Deriving Brown Adipocytes from Brown Adipose (Fat)-Derived Stem Cells

MELVILLE, N.Y., Aug. 31, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the Company) ( BRTX), a life sciences company focused on stem cell-based therapies, today announced that the Japanese Patent Office has issued the Company a patent related to its metabolic ThermoStem Program.

Claims granted under the new patent cover methodologies related to brown adipocytes from human brown adipose (fat)-derived stem cells. Brown adipocytes are a type of fat tissue found in humans that regulate metabolic activity. Initial preclinical research indicates that increased amounts of brown fat in animals may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes.

We are pleased to see that we have been granted a significant patent by the Japanese Patent Office for our ThermoStem Program, said Lance Alstodt, the Companys CEO. The value of our intellectual property assets under our ThermoStem Program continues to grow as we are gaining additional international protection.

About BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders:

Disc/Spine Program (brtxDISC): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a persons own) cultured mesenchymal stem cells collected from the patients bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complementary therapeutic to a surgical procedure. The BRTX-100 production process utilizes proprietary technology and involves collecting a patients bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patients damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have received authorization from the Food and Drug Administration to commence a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease.

Metabolic Program (ThermoStem): We are developing a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in animals may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including, without limitation, those set forth in the Company's latest Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.

CONTACT:Email: [emailprotected]

See more here:

BioRestorative Therapies Receives Patent in Japan Related to its Off-the-Shelf ThermoStem Program - GuruFocus.com

The highly potent and selective non-covalent BTK inhibitor resulted in an overall response rate (ORR) of 52% (95% CI, 38%-65%) in patients with MCL (n = 56), with a 25% complete response (CR) rate, a 27% partial response (PR) rate, and a stable disease rate of 18%.

Among patients who were pretreated with BTK inhibitors (n = 52), the ORR achieved with pirtobrutinib was the same, at 52% (95% CI, 38%-66%); the CR, PR, and stable disease rates were 25%, 27%, and 17%, respectively. Notably, efficacy with the agent was also observed in those who previously underwent stem cell transplant (n = 9/14) or CAR T-cell therapy (n = 2/2), with rates of 64% and 100%, respectively.

The ORR with pirtobrutinib was higher in those with Waldenstrm macroglobulinemia (n = 19), at 68% (95% CI, 44%-87%), which included a PR rate of 47%, a molecular response (MR) rate of 21%, and a stable disease rate of 16%. BTK pretreated patients with Waldenstrm macroglobulinemia (n = 13) experienced an ORR of 69% (95% CI, 39%-91%), with a PR rate of 39%, a MR rate of 31%, and a stable disease rate of 8%.

The ORRs experienced in patients with Richters transformation (n = 8), follicular lymphoma (n = 8), marginal zone lymphoma (n = 9), and diffuse large B-cell lymphoma (n = 25) were 75% (95% CI, 35%-97%), 50% (95% CI, 16%-84%), 22% (95% CI, 3%-60%), and 24% (95% CI, 9%-45%), respectively.

Pirtobrutinib is well tolerated and exhibits promising efficacy in heavily pretreated patients with MCL and other non-Hodgkin lymphomas, lead study author Alvaro J. Alencar, MD, of Sylvester Comprehensive Cancer Center, and colleagues, wrote. Durable responses in BTK pretreated MCL are particularly notable, given poor outcomes with existing therapeutic options.

In the phase 1/2 BRUIN trial, investigators set out to evaluate the safety and efficacy of pirtobrutinib in previously treated patients with advanced B-cell malignancies. To be eligible for participation, patients needed to be 18 years of age or older, an ECOG performance status of 0 to 2, and active disease in need of treatment.

A total of 323 patients were enrolled to the trial; 203 of these patients were enrolled to the phase 1 escalation and expansion portion of the trial, where they received the agent at a once-daily dose ranging from 25 mg to 300 mg, and 120 patients to the phase 3 portion, where they received a once-daily dose of 200 mg.

Key end points of the trial include safety and tolerability, determining the maximum-tolerated dose (MTD) and recommended phase 2 dose (RP2D), pharmacokinetics, and efficacy with respect to ORR and duration of response based on disease criteria.

The median age of participants was 68.3 years, 69% were male, 50% had an ECOG performance status of 0, and the median number of prior lines of systemic therapy was 3. Previous treatments included BTK inhibitors, chemotherapy, anti-CD20 antibody, BCL-2 inhibitors, PI3K inhibitors, lenalidomide (Revlimid), CAR T-cell therapy, autologous stem cell transplant, and allogeneic stem cell transplant. The majority of patients who discontinued prior BTK inhibitors did so because of disease progression.

Among 323 patients included in the safety population, no dose-limiting toxicities were reported and the MTD had not been reached. The most frequent treatment-emergent adverse effects (TEAEs) experienced by 10% or more of patients included fatigue, diarrhea, and contusion. AEs of special interest included bruising, rash, arthralgia, hemorrhage, hypertension, atrial, and fibrillation/flutter.

Of these patients, 1.5% discontinued treatment because of treatment-related AEs. The RP2D for pirtobrutinib was established as once-daily 200 mg. No notable covalent BTK inhibitorassociated toxicities were rarely reported.

Longer follow-up is needed to better understand the pirtobrutinib safety profile associated with chronic administration, the study authors concluded.

See original here:

Pirtobrutinib Exhibits Promising Efficacy in Heavily Pretreated MCL and Other Non-Hodgkin Lymphomas - OncLive

Newswise HOUSTON The University of Texas MD Anderson Cancer Center and Bellicum Pharmaceuticals, Inc. today announced a global option and license agreement covering certain intellectual property and technology rights regarding Bellicums CaspaCIDe (inducible caspase-9, or iC9) safety switch and related technologies, and the use of rimiducid, an agent used to activate the safety switch. Under this agreement, MD Anderson will have the option to incorporate CaspaCIDe into certain cellular therapy programs.

Bellicums CaspaCIDe safety switch may facilitate the use of cell therapies where cytokine release syndrome and neurotoxicities have been observed, in pursuit of novel targets with on-target/off-tumor safety concerns, and in conjunction with next-generation higher potency cell therapy constructs.

We are excited to expand our CaspaCIDe agreement with MD Anderson to include a broader set of programs to benefit cancer patients, said Rick Fair, President and CEO of Bellicum Pharmaceuticals. We believe that our switch technology may enhance the benefit/risk profile of cell therapies. We intend to continue to pursue opportunities to expand its use via external collaborations with other leaders in the field.

Upon exercise of each option typically expected to be upon out-license of an MD Anderson program that incorporates iC9 Bellicum will receive an upfront payment and will be entitled to a percentage of certain consideration paid to MD Anderson by the third party. Bellicum also will receive a single-digit-percent royalty on global sales of the product. Additional details of the financial arrangements are not disclosed. Bellicum and MD Anderson have agreed on the first two programs for development concurrent with the execution of the agreement. This agreement expands upon a previous one, which covers the use of CaspaCIDe in a specific MDAnderson cell therapy program.

The unique inducible caspase-9 technology covered by this agreement has the potential to reduce the risk of serious adverse events associated with cellular therapies and to improve patient outcomes, said Katy Rezvani, M.D., Ph.D., professor of Stem Cell Transplantation and Cellular Therapy atMD Anderson. We have successfully applied the technology to existing cell therapies, and we look forward to the potential future applications made possible by this agreement.

- 30 -

About MD Anderson

The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. The institutions sole mission is to end cancer for patients and their families around the world. MD Anderson is one of only 51 comprehensive cancer centers designated by the National Cancer Institute (NCI). MD Anderson is No. 1 for cancer in U.S. News & World Reports Best Hospitals rankings. It has been named one of the nations top two hospitals for cancer since the rankings began in 1990 and has ranked first 16 times in the last 19 years. MD Anderson receives a cancer center support grant from the NCI of the National Institutes of Health (P30 CA016672).

About Bellicum Pharmaceuticals

Bellicum is a clinical stage biopharmaceutical company striving to deliver cures through controllable cell therapies. The companys next-generation product candidates are differentiated by powerful cell signaling technologies designed to produce more effective CAR-T cell therapies. Bellicums GoCAR-Tproduct candidates, BPX-601 and BPX-603, are designed to be more efficacious CAR-T cell products capable of overriding key immune inhibitory mechanisms. More information about Bellicum can be found at http://www.bellicum.com.

More:

MD Anderson and Bellicum Announce Additional License Agreement for Use of CaspaCIDe Safety Switch - Newswise

Hematopoietic somatic cell Transplantation (HSCT) may be a specialized sort of blood somatic cell transplant therapy. The term hematopoietic refers to the function of the stem cells in citizenry . Stem cell refers to specialized somatic cell types which are capable of developing into specific cells like bone, muscle, blood, and nerve cells.

The PDF for the study can be requested using the following link: https://www.coherentmarketinsights.com/insight/request-pdf/1250

Hematopoietic somatic cell transplantation are often utilized in the treatment of certain cancers of the blood or bone marrow, like myeloma or leukemia. High prevalence of such diseases is predicted to assist in growth of the hematopoietic somatic cell transplantation (HSCT) market. consistent with Leukemia and Lymphoma Society, 176,200 people within the US are expected to be diagnosed with leukemia, lymphoma or myeloma in 2019.

The hematopoietic somatic cell transplantation (HSCT) market in North America is witnessing high growth, due to high adoption of allogeneic hematopoietic somatic cell transplant. Around 30,000 patients undergo allogeneic hematopoietic somatic cell transplant annually within the us .

Hematopoietic cell transplantation is that the transplantation of stem cells, generally derived from bone marrow, duct , or peripheral blood. It also can be allogenic, autologous or syngeneic. the foremost common sort of somatic cell transplant is that the allogenic transplant, which is actually the method of harvesting such stem cells that have the power to become many various specialized cell types, like bone, kidney, heart, liver, lungs, pancreas, nervous, and immune cells. However, approximately 20% to 85% of the patients develop acute Graft Versus Host Disease that affects the skin, gut, or liver. Such scenario hinders the expansion of hematopoietic somatic cell transplantation (HSCT) market.

There are different methods of transplant. just in case of a basic transplant, the stem cells are directly transplanted into an individuals veins, while a minimal invasive procedure also referred to as a micro-implantation requires the injection of the cells into the patients veins. supported the precise needs of the patient, the precise sort of transplant is completed . for instance , a toddler who has undergone bone marrow transplantation can continue to possess other somatic cell types utilized for an equivalent purpose. this is often one among the foremost commonly performed sorts of transplants.

High prevalence of red blood cell anemia is additionally expected to assist in growth of the hematopoietic somatic cell transplantation (HSCT) market. Specially created somatic cell therapies are often utilized in the treatment of red blood cell anemia. These cells are basically taken from the bone marrow of the person then induced to make a thick, jelly like substance. The patient will got to take medicine for a couple of days after the procedure to assist his bodily process the cells.

Hematopoietic cell transplantation has its own set of complications, which limit the expansion of the hematopoietic somatic cell transplantation (HSCT) market. a number of these include infection, allergies , bleeding, and scarring. Infection can occur if theres a severe immune deficiency. The patient also will need to take antibiotics to clear up the infections. If the stem cells are used, they need to be grown under very strict conditions to avoid rejection. Most surgeons attempt to perform this transplant first on those people that suffer from serious diseases like leukemia or cancer as these are the people that stand the simplest chance to achieve success .

Competitive Landscape

Key players operating in the Hematopoietic Stem Cell Transplantation (HSCT) Market are Pluristem Therapeutics Inc., CellGenix GmbH, Regen Biopharma Inc., Lonza Group, Kiadis Pharma, Taiga Biotechnologies, Inc., Takeda Pharmaceutical Company Limited, Escape Therapeutics, Inc., Bluebird Bio, Talaris Therapeutics, Inc., Marker Therapeutics Inc., and Stempeutics Research Pvt Ltd.

We also offer 15% FREE Report customization.Get This premium report with Instant US$ 2000 discount @ https://www.coherentmarketinsights.com/promo/buynow/1250

Contact Us

Mr. ShahCoherent Market Insights1001 4th Ave, #3200Seattle, WA 98154Phone: US +12067016702 / UK +4402081334027Email: sales@coherentmarketinsights.com

See the article here:

Hematopoietic Stem Cell Transplantation (HSCT) Market by Sales, Revenue, Price and Gross Margin (2021-2027) UNLV The Rebel Yell - UNLV The Rebel Yell

Cultures with treated stem cells had a 50% higher stem cell survival rate than untreated cultures. Image by carolem41

Treating equine donor stem cells with a growth factor called TGF-2 may allow them to avoid tripping the immune response in recipients, according to new research.

The work carried out at North Carolina State University could simplify the stem cell treatment process for ligament and tendon injuries in horses, and may also have implications for human stem cell therapies.

Mesenchymal stem cell therapy is a promising avenue for treating musculoskeletal injuries, particularly tendon and ligament injuries, in horses.

Mesenchymal stem cells are adult stem cells found in bone marrow that act as repair directors, producing secretions that recruit healing-related paracrine factors to the site of injury.

Just as blood cells have types, depending upon which antigens are on the blood cells surface, mesenchymal stem cells have differing sets of major histocompatibility complex molecules, or MHCs, on their surfaces.

If the MHCs of donor and recipient arent a match, the donors stem cells cause an immune response. In organ transplants, MHCs are carefully matched to prevent rejection.

These treatments arent like a bone marrow transplant or an organ transplant, says Lauren Schnabel, associate professor of equine orthopedic surgery at the university and corresponding author of the study, reported in the journal Frontiers in Cell and Developmental Biology.

Since the mesenchymal stem cells are being used temporarily to treat localized injury, researchers once thought that they didnt need to be matched that they wouldnt cause an immune response. Unfortunately, that isnt the case.

Schnabel and Alix Berglund, a research scholar at the university and lead author of the paper, wanted to find a way to use mesenchymal stem cell therapy without the time, effort and additional cost of donor/recipient matching.

Since these cells dont have to be in the body as long as an organ does, hiding them from the immune system long enough for them to secrete their paracrine factors could be a way around donor/recipient matching, Berglund says. Downregulating expression of the MHC molecules could be one way to do this.

The researchers cultured stem cells and lymphocytes, or T cells, from eight horses, cross-pairing them in vitro so that the stem cells and lymphocytes had differing MHC haplotypes.

In one group, stem cells had been treated with transforming growth factor beta (TGF-2) prior to being added to the lymphocytes in the culture media; the other group was untreated. TGF-2 is a cell-signaling molecule produced by white blood cells that blocks immune responses.

Cultures with treated stem cells had a 50% higher stem cell survival rate than untreated cultures.

We use mesenchymal stem cells to treat musculoskeletal injuries particularly tendon injuries in horses very effectively, Schnabel says.

And while you can extract the secretions from the stem cells, you get better results with the cells themselves. Stem cells arent just a reservoir of secretions, theyre a communications hub that tells other cells what they should be doing. So finding a way to utilize these cells without stimulating immune response gives us better treatment options.

This is a promising pilot study, Berglund says. Our next steps will be to further explore the immune response in vivo, and to look at human cells in vitro, as this work has excellent potential to help humans with these injuries as well.

The research was supported by the National Institutes of Health and the Morris Animal Foundation. Research specialist Julie Long and statistician James Robertson, both with the university, also contributed to the work.

TGF-b2 Reduces the Cell-Mediated Immunogenicity of Equine MHC-Mismatched Bone Marrow-Derived Mesenchymal Stem Cells Without Altering Immunomodulatory PropertiesAlix K. Berglund, Julie M. Long, James B. Robertson, Lauren V. SchnabelCell Dev. Biol., 04 February 2021 https://doi.org/10.3389/fcell.2021.628382

The study, published under a Creative Commons License, can be read here.

Original post:

Researchers curb local immune response in horses receiving stem cell injury therapy - Horsetalk

The United States Food and Drug Administration (FDA) has given the green light for experimental trials of a truly new therapy for Type 1 diabetes.

The new therapy, named VX-880, is referred to in a press release as an investigational stem cell-derived, fully differentiated pancreatic islet cell therapy to treat T1D. In plain English, VX-880 uses laboratory stem cells that have been grown into insulin-producing pancreatic beta cells. Those cells are then transplanted into a patient with Type 1 diabetes, and act just as the patients own beta cells should, hopefully restoring the bodys ability to sense glucose levels and secrete insulin in response.

Its an exciting moment for the treatment. Vertex, the business developing VX-880, has already run successful proof-of-concept animal testing. The therapy is ready for the next huge hurdle, tests in humans.

While diabetes technologies and therapies have improved at a rapid pace over recent decades, there has still be very little meaningful work done on reversing the root cause of diabetes: the autoimmune reaction that destroys the beta cells in the pancreas that secrete insulin. A therapy that could restore pancreatic function could potentially function as an actual cure, correcting the root dysfunction rather than just mitigating its effects.

For now, thats still a dream there is a very long road for the therapy to travel before we can realistically talk about it as an option for patients. People with diabetes can be understandably skeptical about potential cures, having heard about so many breakthroughs over the years that have thus far amounted to little or nothing. Only a thin minority of the drugs that begin Phase 1 clinical testing ever make it to the market. Even if it works, we dont yet know if VX-880 could wholly restore beta cell function, or only partially restore it, necessitating the continued use of some exogenous insulin.

While practical application may be a long way away, the therapy has already come pretty far to get to this point. Its genesis began years ago with the work of Dr. Douglas Melton of the Harvard Stem Cell Institute. Melton founded a company, Semma Therapeutics, to work on the therapy. Last year, Semma Therapeutics was acquired by a larger biotech firm, Vertex, for nearly $1 billion. Thats an eye-opening bet on the technology.

Dr. Melton is extremely optimistic about his breakthrough. In a 2019 interview, he stated, Im convinced that those cells will cure the disease.

Of course, even a Type 1 diabetes cure could come with strings attached. VX-880, for example, will require the chronic administration of concomitant immunosuppressive therapy in order to prevent the new islet cells from rejection by the bodys immune system. No word yet on how burdensome immunosuppressive therapy might be for patients. Vertex has also investigated other methods of protecting new islet cells from the immune system; another concept would implant new islet cells in a kind of porous tea bag that would allow both glucose and insulin to filter through, but block immune cells.

Initial trials will restrict VX-880 to some of the patients most in need of a radical therapy, those with hypo unawareness and a history of severe hypoglycemia. The company will recruit about 17 patients for the Phase 1 testing.

Here is the original post:

FDA Green Lights Trials of New Type 1 Diabetes Stem Cell Therapy - A Sweet Life

SAKAI, Japan Just like humans, mans best friend deals with all sorts of chronic and degenerative conditions as they age. For dogs however, scientists have fewer ways of reversing life-threatening illnesses compared to human patients. Now, a team in Japan has successfully developed a technique which creates new stem cells from a dogs blood. Their study opens the door for new therapies which can regenerate a dogs body just like stem cells do in people.

In humans, these baby cells have the potential to grow into a variety of specialized cells, an ability called pluripotency. After scientists transplant these stem cells into a patient, they guide their differentiation into the specific kind of cells which completes their task. The new cells can then regenerate damaged tissues, reversing the effect of various diseases. While stem cell research for humans is a widely studied topic, researchers say little work is done with pets.

The new study, led by Associate Professor Shingo Hatoya from Osaka Prefecture University, focuses on induced pluripotent stem cells (iPSCs) in canine blood samples. Study authors say iPSCs are a type of stem cell which can be programmed from a developed cell. Scientists can do this by introducing specific genes into the cell. The genes code for specific proteins (transcription factors) which trigger the change from a developed cell into a pluripotent stem cell.

Another good thing about iPSCs is they multiply rapidly, providing a sustainable supply of usable stem cells for medical treatments.

We successfully established an efficient and easy generation method of canine iPSCs from peripheral blood mononuclear cells Dr. Hatoya in a university release.

The study authors call this a breakthrough in veterinary science. Hatoya hopes in the near future, it may be possible to perform regenerative medicinal treatments in dogs.

This isnt the first time scientists have experimented with iPSCs from canine blood cells. Researchers say these attempts used viral vectors to deliver the stem cell-triggering transcription factors.

In the new study, the Japanese team tested a different combination of factors to create pluripotency. Most importantly, researchers say they had to control how the reprogrammed cells multiplied in the host.

Scientists use viral vectors, which encode these transcription factors, to infect cells and convert them into iPSCs. Unfortunately, since these vectors merge with the hosts genetic material, these pluripotency factors can actually cause tumors if they are transplanted into a dog.

To avoid this, researchers created footprint-free stem cells using a special type of viral vector. This particular vector generates iPSCs without mixing with the hosts genes. It can also be automatically silenced by microRNAs in the cells. The OPU team grew these cells in a special environment which contained a small-molecule cocktail that enhances pluripotency. The results successfully produced cells which developed germ layers the basis of all organs.

Study authors say their findings provide a clear path to easy stem cell treatments for dogs. However, they add that their research may also have a ripple effect in the human medical world as well.

We believe that our method can facilitate the research involving disease modeling and regenerative therapies in the veterinary field, Dr. Hatoya says. Dogs share the same environment as humans and spontaneously develop the same diseases, particularly genetic diseases.

The team believes finding a cure for diseases in mans best friend may also open the door to curing illnesses still plaguing mankind.

The study appears in the journal Stem Cells and Development.

More:

Breakthrough stem cell therapy may reverse life-threatening conditions in dogs - Study Finds

Following stem cell transplant or treatment with CAR T-cell therapies, patients with hematologic malignancies and coronavirus disease 2019 (COVID-19) tend to have favorable outcomes, especially if they are diagnosed in complete remission (CR) and further out from their cell infusion, according to Miguel-Angel Perales, MD, underscoring that care should not be delayed despite the ongoing pandemic.

Delayed therapy results in patients with relapse or progression of disease who did not receive the intended cellular therapy; [weve seen this happen] in 34% of cases, Perales, chief of the Adult Bone Marrow Transplant Service at Memorial Sloan Kettering Cancer Center (MSKCC), said during a presentation delivered at the 2021 AACR Virtual Meeting on COVID-19 and Cancer.1 Given that we can avoid the risk of nosocomial transmission, I think this clearly indicates that we should be careful about how we manage these patients and not try to delay their care.

In his talk, Perales highlighted registry data detailing the impact of the pandemic on cellular treatment in patients with cancer, outcomes of patients who were infected with the virus and received hematopoietic cell transplantation, and the impact of virus-related delays in care.

Data reported to the ASH Research Collaborative COVID-19 Registry for Hematology, a global reference tool available to the public, showed that as of January 15, 2021, a total of 813 malignant and non-malignant cases of COVID-19 were reported, with just over 500 cases reported in the United States alone.2

When looking at cellular therapies received prior to a diagnosis with the virus, 10 patients had received CAR T-cell therapies (6 recovered, 4 died), 46 patients had undergone allogeneic stem cell transplantation (34 recovered, 7 died, 5 had unknown outcome), and the majority, or 78 patients, had undergone autologous stem cell transplantation (67 recovered, 7 died, 4 had unknown outcome).

An earlier analysis of data collected from this registry showed that among the first 250 patients for whom data were collected, the overall mortality rate was 28% (95% CI, 23%-34%).3 However, in patients with moderate to severe COVID-19 infection, the mortality rate was even higher, at 42% (95% CI, 34%-50%). This is a condition that has significantly impacted our patients with hematologic malignancies, noted Perales.

Another registry, of the Center for International Blood & Marrow Transplant Research (CIBMTR), requires the inclusion of outcomes of patients who have undergone transplantation or received CAR T cells.4 As of January 15, 2021, data for 1258 patients from 195 centers were reported to the registry and showed that 50.08% of patients had undergone allogeneic transplantation and 44.66% had undergone autologous transplantation. Only a small percentage of patients received cell therapy, according to Perales.

The age of patients at the time of infection ranged from less than 20 years to older than 70 years, with the majority of patients between the ages of 60 years and 69 years. When looking at infections by region, 29.35% of cases were reported in the Midwest, 23.44% were reported in the Northeast, and 22.73% were reported in the South. The majority of cases occurred within the first 2 years of their infusion. A total of 614 casesalmost half of all patientshad their infection resolve, while 58 experienced improvement; 187 patients had died.

In a subsequent paper, investigators examined risk factors associated with death from COVID-19 in recipients of allogeneic transplantation based on data from the CIBTR registry.5 Results from the multivariate analysis showed that age greater than 50 years (P = .016), male gender (P = .006), and COVID-19 infection in less than 12 months following transplantation (P = .019) were all significantly associated with increased risk of death.

Interestingly, race and ethnicity were not significant in this series, noted Perales. Similarly, when we look at patients [who have undergone] autologous transplant, the only factor that we saw was the diagnosis of lymphoma versus myeloma. Other factors were not significant.

In another analysis, investigators examined outcomes of patients following transplant who were infected with the virus at MSKCC. Of the first 77 patients diagnosed between March 15, 2020 and May 7, 2020, 37 had undergone autologous transplant, 35 had undergone allogeneic transplant, and 5 had received CAR T-cell therapy.6

The disease distribution was as expected, according to Perales. Thirty-eight percent of patients had plasma cell disease, 23% had acute leukemia, 23% had aggressive non-Hodgkin lymphoma (NHL), 5% had Hodgkin lymphoma, 4% had chronic myeloid leukemia, 4% had myelodysplastic syndrome, and 3% had indolent NHL.

When you look at day [of infection] post infusion, you see there was a significant range, said Perales. In fact, the number of patients were diagnosed with COVID-19 several months or even years after their cell therapy. These are the demographics of 77 patients, but this is representative of the patients that we transplant at our center.

Notably, 44% of patients did not have any comorbidities. Investigators also examined the home medications that patients were receiving at the time of their COVID-19 diagnosis. Here, 10 patients were receiving steroids, 18 were receiving immunomodulatory agents, 4 were receiving anticoagulation agents, and 14 were receiving immunosuppressive drugs.

Almost half, or 48%, of patients had mild COVID-19 infection, so they were not admitted to the hospital. Twenty-six percent of patients had moderate infection, and thus, were admitted to the hospital, while 22% had severe infection and were either admitted to the intensive care unit or died.

In that group, the majority of them actually had active malignancy, unlike the other 2 groups where the majority actually were in remission, said Perales. Patients who required high levels of oxygen [were often those who] had active malignancy.

Results from a univariate analysis looking at the predictors of disease severity revealed significant associations between the presence of comorbidities and infiltrates on imaging at the time of diagnosis. Overall, however, we were able to see favorable outcomes with patients after COVID-19 infection, said Perales. Two-thirds of patients actually had a resolution. We did see 14 deaths, which represented 18% of patients. This was 41% of patients who were admitted, but particularly those with an active malignancy.

Among patients who were admitted to the hospital but had a malignancy that was in remission, the mortality rate was 21%. This was due, in part, to the fact that in many cases, patients or their family members decided to forego aggressive medical care.

Additional data revealed that COVID-19 was linked with a drop in lymphocyte populations across the board, added Perales. Notably, lymphopenia with COVID-19 was not found to impair long-term immune reconstitution in patients who had undergone bone marrow transplant.

When looking at survival in patients after infection with COVID-19, overall outcomes were found to be favorable.

Investigators also examined the risk of nosocomial infections in patients who had undergone transplantation or received cellular treatment in light of the pandemic. They looked at a series of 44 cases.

In March 2020, 2 healthcare workers were exposed at MSKCC and 3 patients had documented COVID-19 infection. One patient was receiving treatment in the inpatient setting, but the patient did have frequent visits from family members, according to Perales. So, its unclear when or how the exposure occurred, Perales said. The patient ended up dying.

Two additional patients may have been exposed in the donor room while they were collecting the stem cell from the autologous transplant, added Perales. One patient eventually died from the virus.

Again, its unclear whether these patients were infected in the center or in the community, as COVID-19 was very prevalent at the time, said Perales. Importantly, we have not seen any additional cases of potential or definite COVID-19 nosocomial infection since March 2020 at our center.

When examining the impact of the pandemic on treatment delays, in March 2020, investigators started to prospectively collect data from patients whose transplant or cellular therapy was delayed as a result of the impact of the virus on resources at the hospital, particularly the capability of using intensive care unit beds.1

Results showed that 85 patients delayed treatment; of those patients, 29 have not received their intended cellular treatment. Sixteen were supposed to receive autologous transplant, 12 were supposed to undergo allogeneic transplant, and 1 was supposed to receive CAR T-cell therapy.

Of the 56 patients who eventually proceeded to treatment, 62% received autologous transplant, 67% received allogeneic transplant, and 86% received CAR T-cell therapy. The biggest reason for not proceeding to treatment with autologous transplant and CAR T-cell therapy was because they were deferred due to good disease control. Other reasons included was because of a new comorbidity (12%) or they died from the virus. The most prominent reason for not proceeding to allogeneic transplant during the pandemic was progression of disease (42%).

We conclude that patients who are recipients of allogeneic transplant, and particularly those with acute leukemia, as much as possible should proceed to their indicated therapy and not be delayed, concluded Perales.

See more here:

Perales Examines the Impact of COVID-19 on Recipients of Cellular Therapies for Cancer - OncLive

Dublin, Feb. 05, 2021 (GLOBE NEWSWIRE) -- The "Global Stem Cell Partnering Terms and Agreements 2010-2020" report has been added to ResearchAndMarkets.com's offering.

The Global Stem Cell Partnering Terms and Agreements 2010-2020 report provides comprehensive understanding and unprecedented access to the stem cell partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter Stem Cell partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.

This report provides details of the latest Stem Cell agreements announced in the life sciences since 2010.

The report takes the reader through a comprehensive review Stem Cell deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Stem Cell partnering deals.

The report presents financial deal term values for Stem Cell deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

One of the key highlights of the report is that over 650 online deal records of actual Stem Cell deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

A comprehensive series of appendices is provided organized by Stem Cell partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Stem Cell partnering and dealmaking since 2010.

Report scope

Stem Cell Partnering Terms and Agreements includes:

In Global Stem Cell Partnering Terms and Agreements 2010-2020, the available deals are listed by:

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Stem Cell dealmaking2.1. Introduction2.2. Stem Cell partnering over the years2.3. Most active Stem Cell dealmakers2.4. Stem Cell partnering by deal type2.5. Stem Cell partnering by therapy area2.6. Deal terms for Stem Cell partnering2.6.1 Stem Cell partnering headline values2.6.2 Stem Cell deal upfront payments2.6.3 Stem Cell deal milestone payments2.6.4 Stem Cell royalty rates

Chapter 3 - Leading Stem Cell deals3.1. Introduction3.2. Top Stem Cell deals by value

Chapter 4 - Most active Stem Cell dealmakers4.1. Introduction4.2. Most active Stem Cell dealmakers4.3. Most active Stem Cell partnering company profiles

Chapter 5 - Stem Cell contracts dealmaking directory5.1. Introduction5.2. Stem Cell contracts dealmaking directory

Chapter 6 - Stem Cell dealmaking by technology type

Chapter 7 - Partnering resource center7.1. Online partnering7.2. Partnering events7.3. Further reading on dealmaking

Appendices

For more information about this report visit https://www.researchandmarkets.com/r/c8ppmy

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Originally posted here:

Global Stem Cell Partnering Terms and Agreements Directory 2020: Company AZ, Headline Value, Stage of Development at Signing, Deal Component Type,...

During a Targeted Oncology Case-Based Peer Perspectives virtual event, Jason Westin, MD, MS, director, Lymphoma Clinical Research, section chief, Aggressive Lymphoma, and associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, evaluated the management of a 63-year-old patient with diffuse large B-cell lymphoma (DLBCL).

Targeted OncologyTM: What is your initial impression of the therapy used in this case? How would you treat the patient?

WESTIN: Theres not a right or wrong approach here. We dont have any randomized data yet saying that R-CHOP is clearly wrong. We have data from retrospective [analyses] from MD Anderson Cancer Center, as well as a cooperative group publication, saying that outcomes appear inferior with R-CHOP versus R-EPOCH [rituximab, etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin]. But there are all types of biases when choosing to treat with R-CHOP for that patientis it because she was older and frail and couldnt tolerate EPOCH? [Its not a surprise that] elderly and frail patients dont live as long as patients who are more fit. Sometimes those kind of analyses have biases built into them that might favor the more aggressive treatment, just because of whom youre choosing to give it to. But I think most people feel that if the patient is able to tolerate a change in treatment, at least try it, at least see whether theyre able to tolerate R-EPOCH.

For many patients, R-EPOCH is not that much more toxic than R-CHOP. Its the same drugs; etoposide is added and stretched over 5 days, basically continuous infusion for the first 4 days and then the cyclophosphamide on day 5. It is the same dose for CHOP. So its more complicated for oncologists to give than the [regimen of] 1 day every 3 weeks in the infusion area. But in terms of patients, the adverse effects [AEs] generally line up to be similar. I also...give CNS [central nervous system] prophylaxis. Patients with double-hit lymphoma have a higher risk of CNS disease. Its not through the roof, but the incidence is usually somewhere in the 10% to 20% range of patients who could have a relapse in the brain.

How do you prefer to give patients CNS prophylaxis?

Theres no wrong answer, so whatever you like to use is OK. Many people use intrathecal [IT] chemotherapy because its easier than having to stop CHOP and give methotrexatewhat if theres renal dysfunction, or what if the liver function tests [get worse], and then you have to delay the next cycle?

For EPOCH, cytopenias are sometimes a challenge in that second week when youre trying to give somebody IT or intravenous [IV] methotrexate. Many people would give it as concurrent IT with EPOCH. There were data from the 2020 American Society of Hematology annual meeting that IT and IV might not [make a difference in AE recurrence].1 There was a large meta-analysis from multiple sites across the United States and internationally showing that for patients who are at high risk of CNS relapse, whether they receive treatment via IT or IV, both [delivery methods] still have a high risk of relapse in the brain. This is totally controversial, and the [definitive] answer is that we dont know.

Most people will continue to use IT or IV methotrexate. You just want to make sure if youre giving IV that youre maintaining the schedule and dosing intensity for the systemic chemotherapy, that youre not compromising and [there are] 5 weeks between doses of EPOCH so you can give them methotrexate in the middle.

What other regimens besides EPOCH are being used in this setting?

There are places around the world that dont use EPOCH. They use hyper-CVAD [cyclophosphamide, vincristine, doxorubicin, dexamethasone] or CODOX-M [cyclophosphamide, vincristine, doxorubicin, high-dose methotrexate]. In the United States, EPOCH [in] publications from the National Cancer Institute from Wyndham Wilson, MD, PhD, and Kieron Dunleavy, MD, showed good results in the mediastinal subtype and some patients with Burkitt lymphoma; Ive shifted over to using it.

EPOCH is a fairly widely used regimen, but its not [wrong to use] hyper-CVAD, CODOX-M, or the intensified regimen from Europe. Its basically [moving up] from R-CHOP to something more intense.

Which trials are relevant right now for the population with DLBCL?

Axicabtagene ciloleucel [axi-cel (Yescarta)] was the first CAR [chimeric antigen receptor] T cell approved for adults with DLBCL in the United States, based on the pivotal trial [ZUMA-1 (NCT02348216)].2 [Eligible patients had] no response to last chemotherapy or relapse less than 12 months after autologous stem cell transplant, so basically patients with refractory disease or who were relapsing post transplant. They had to have [received] a prior [anti-CD20 therapy] and a prior anthracycline, which most patients with DLBCL have had.

The trial enrolled 108 patients in 2 cohorts. The [cohort] well focus on is the DLBCL cohort. Generally, the schema for CAR T cells [is] a lymphodepleting chemotherapy thats given ahead of timecyclophosphamide and fludarabine. This is to help the T cells grow, not to control disease; this is to get a favorable cytokine and microenvironment for cell growth when those T cells are infused. These are autologous cells. Its a 1-time treatment of 2 106 CAR T cells, and in this trial, 99% of patients who were enrolled were able to [have their cells] manufactured and 91% were dosed with the cells.

This [study is] changing our management of disease for patients because the overall response rate [ORR] was 83% and 58% had a complete response [CR].3 In this population post transplant or in those who are refractory to heavy-duty chemotherapy, there is a progression-free survival [PFS] of 5.9 months. There was a [significant] proportion of patients who otherwise probably would have died of their disease.

What other CAR T-cell therapies are available?

The second CAR T-cell therapy that was approved for adults with DLBCL, tisagenlecleucel [tisa-cel; Kymriah], was based on findings of the pivotal JULIET study [NCT02445248].4 This schema was basically the same for all the CAR T-cell therapies where patients undergo apheresis, which is similar to but not the same for transplant apheresis. This is [for patients] not getting CD34-positive cells...giving T cells that are cryopreserved for tisa-cel. Theyre then shipped to manufacturing. Patients could get bridging therapy on this clinical trial, which was not the case for the ZUMA-1 trial. They had undergone lymphodepletion with chemotherapy for 5 days, 4 days, and 3 days before receiving the infusion of the CAR T cells on day 0, and then theyre followed.

The results of this clinical trial [showed] ORR was a little lower at 52% and CR rate at 40% [compared with ZUMA-1]. But for those with a CR, there was an impressive Kaplan-Meier curve that showed patients being a year or more out, and 80% or more of them are holding their response. Median overall survival was 12 months for patients who were infused on this study.

How do the available CAR T-cell therapies compare?

Comparing the 2 products I just mentioned that are already FDA approved, as well as the one with impending approval, lisocabtagene maraleucel [liso-cel]...there was fairly robust follow-up now, 27 months, 14 months, 18 months [with axi-cel, tisa-cel, and liso-cel, respectively]; were seeing median PFS level out around 6 months.3-5 We see the same plateau occur in all these CAR T-cell studies, where theres a proportion somewhere in the 30% to high 40% range of patients who are long-term responders. With tisa-cel and liso-cel, the median overall survival was 12 months and 21 months, respectively; for axi-cel, its not reached, which is awfully impressive for this otherwise refractory population.

The trade-off is that it works but can be toxic. The cytokine release syndrome that people talk about, which is the dreaded complication, was seen in the studies at relatively low frequency and was characterized as grade 3 or 4. The tisacel grade 3/4 AEs were higher [23%], but it used a different grading system than the other 2. If [the AEs were] graded with the same system, it was pretty similar, around 10% or so. All 3 of them have an incidence of grade 3 or 4 cytokine release syndrome, but its relatively infrequent. The neurotoxicity is different, however, and for axi-cel, about 1 in 3 patients will have grade 3 or 4 neurotoxicity, which is sometimes prohibitive for this being utilized outside specialized centers that do this frequently. These are some of the reasons that it can be a challenge to administer these drugs.

What other kinds of drugs are available in this setting, and what data support them?

Another option approved recently is polatuzumab vedotin [Polivy], an antibody-drug conjugate, plus bendamustine and rituximab [BR].6 Approval was based on a randomized phase 2 trial for patients with relapsed disease, and it was randomized to either BR or polatuzumab/BR. Patients could not receive [this regimen] after transplant, either allogeneic or autologous, if they had significant neuropathy or if they were eligible for autologous transplant.

The patients ages were typical for this population. The International Prognostic Index score was fairly well balanced, although it was a bit higher risk in the BR arm. The median number of prior lines of treatment was 2 in both arms and about the same for the proportion of patients who had more than 3 prior lines. Seventy-five percent of patients [in the polatuzumab arm] and 85% [in the BR-only arm] had been refractory to the most recent therapy, [so this was a] highly refractory group. The germinal center B-cell subtype was fairly even between these groups.

Polatuzumab had an objective response rate of around 45% and a CR rate of 40%. Bendamustine is not the best drug combination for patients, [and BR had a] 17.5% objective response rate.

The PFS was statistically significant, 9.5 versus 3.7 months for the investigator review as well as the central review [HR, 0.36; 95% CI, 0.21-0.63; P < .001]. Every subgroup favored the polatuzumab/BR regimen.

Bendamustine has toxicities, but polatuzumab/BR has a bit more in terms of the cytopenias. Neutropenia was more common. Febrile neutropenia was fairly even. A bit more neutropenia but not more febrile neutropenia. Then the peripheral neuropathy, which we know from this drug class...is an issue. Not so much with bendamustine, but about 40% of patients had some degree of mild neuropathy on the polatuzumab side.

Have there been other approvals in this setting?

Selinexor [Xpovio] was approved [in 2020 based on results of the SADAL] trial [NCT02227251].7 This evaluated patients with relapsed DLBCL who were transplant ineligible. They had to be at least 60 days post treatment or 14 weeks if they had less than a partial response. So this was not a refractory population.

The response rates [were] 28% ORR, 12% CR, and its fairly similar across the different cell of origin subtypes. There was a good group of patients who got some benefit even if they didnt get a CR, and theres no patient variable that came out as a predictor for response.

Treatment AEs [included] thrombocytopenia as the big one. It was basically 60% or so of patients have some degree of thrombocytopenia; 15%, grade 4. About half the patients had some nausea, some anorexia, and some weight loss. Seventeen percent of patients discontinued because of treatment AEs, and 5 patients died because of treatment AEs.

See the original post:

Westin Evaluates Management of DLBCL With CAR T-Cell Therapy - Targeted Oncology

Researchers at the Catholic University of Korea St. Marys Hospital have recently proved the efficacy of bone marrow-derived stem cells to treat ototoxicity hearing loss, the hospital said Thursday.

The team, led by Professor Park Kyoung-ho of the Department of Otolaryngology, conducted an experiment on animal models with ototoxic sensorineural hearing, or sudden hearing loss.

They utilized Catholic MASTER cells, bone marrow stem cells developed by the Catholic Institute of Cell Therapy, to compare the stem cell injection group with the controlled group.

The result showed that animals started to recover their hearing after three weeks. Five weeks later, they recovered normal hearing at 8000Hz, 16000Hz and 32000Hz frequency.

Ototoxic hearing loss is caused when a person ingests chemicals or certain medications that adversely affect the inner ear functions. Major symptoms related to the illness are dizziness, false hearing, and hearing loss, which permanently defects hearing functions. Elders with such symptoms should have medical consultations as they are a high-risk group, the hospital said.

We have proved the efficacy of our bone marrow stem cells in recovering hearing, said Professor Park, who doubles as the director of the Stem Cell Institute. Through the results, we expect to provide new treatment opportunities for patients with hearing loss.

The test results were published in the Korean Journal of Otorhinolaryngology-Head and Neck Surgery.

See the rest here:

Stem cells' efficacy confirmed in treating ototoxic hearing loss - Korea Biomedical Review

ISLAMABAD-London Aesthetics & Rejuvenation Centre [LARC], helmed by Dr. Tauqir Ahmad, proudly announced their collaboration with the worlds leading stem cell therapy, R3 Stem Cell International to introduce the stem cell therapy treatments in Pakistan, with an exclusive experiential afternoon held at LARC in Lahore recently.Dr. David L. Greene, the visionary founder & CEO of R3 Stem Cell International flew in from USA to attend the event, where he talked about his vision for Pakistan while giving consultations to the attendees. The event was further attended by some of Lahores most distinguished and influential media personalities. The event and PR was managed by Lotus.Dr. Tauqir Ahmad, regarded as one of the first practitioners in the UK to start practicing the injections of Botox, launched LARC in Pakistan with a mission to achieve excellence in aesthetics and to be at the forefront of research and development of new treatments. With this collaboration, Dr. Tauqir Ahmad has brought the worlds most scientifically advanced stem cell therapy and treatments to Pakistan for this ever-expanding industry which will be executed by his expert team in Pakistan including Dr. Badie Idris (Medical Director), Dr. Sara Mubasshar (Clinical Dermatologist), Dr. Yasmin Chaudhry (Aesthetic Physician), Dr. Zulfiqar Salim (Plastic Surgeon), Dr. Saeed Qureshi (Bariatric Surgeon), Dr. Sheila Anwar (Aesthetic Gynaecologist) and Dr. Abdul Basit (Orthopaedic Surgeon).

Original post:

Stem cell therapy treatment introduced in Pakistan - The Nation

The report contains an overview explaining Stem Cell Therapy Market on a world and regional basis. Global Stem Cell Therapy market report is a definitive source of information and provides the latest market research, evolving consumer trends with actionable information about new players, products, and technologies. Our analysts have statistical data to provide information about the statistical report, including the factors that drive and impede the market growth.

The study is an integrated effort of primary and secondary research. The report provides an overview of the key drivers affecting the generation and growth limitation of Stem Cell Therapy market. In addition, the report also examines competitive developments, such as mergers and acquisitions, new partnerships, new contracts, and new products in the world market. The past trends and future prospects presented in this report make it very comprehensible to market analysis. Furthermore, the latest trends, product portfolio, demography, geographic segmentation, and market regulatory framework Stem Cell Therapy were also included in the study.

Description:

Market Segment according to type covers:

Market segment by applications may be broken down into:

Request a sample report in PDF format@ https://www.regalintelligence.com/request-sample/201348

Fundamental Highlights

And More

The following section also highlights the supply-to-consumption gap. In addition to the above data, the growth rate of Stem Cell Therapy market in 2026 is also explained. Moreover, consumption charts by type and application are also given.

Purpose of Studies:

World Market Report Stem Cell Therapy Industry primarily covers 10 sections in the table as follows:

Complete the pre-order requisition form for the report: @ https://www.regalintelligence.com/enquiry/201348

Thank You.

Go here to read the rest:

Stem Cell Therapy Market Information, Figures and Analytical Insights 2020 2026 - The Courier

Vancouver, British Columbia, Jan. 29, 2021 (GLOBE NEWSWIRE) -- Stem Cell Therapy Market Size to Reach USD 5,040 Million by 2028 | Rising Public-Private Investments and Developing Regulatory Framework for Stem Cell Therapeutics will be the Key Factor Driving the Industry Growth, States Emergen Research

The global stem cell therapy market size was valued at USD 342.7 Million in 2019 and is anticipated to reach USD 3,693.6 Million by 2027 at a CAGR of 36.2%, over the forecast period, according to most recent analysis by Emergen Research.

Growing prevalence of chronic diseases will drive the growth of the stem cell therapy market. Increased investment in research activities, development of advanced genetic techniques, and rise in public-private partnership will contribute to the growth of the stem cell therapy market.

Stem cells are used to improve health and manage disease. The growing popularity of regenerative medicine has encouraged the growth of stem cell therapy market. Regenerative medicines are used to replace, repair, and regenerate tissues affected by disease, injury, and aging process. Regenerative medicines are used in research to find a cure for diabetes, Parkinson's, and Alzheimer's disease.

Claim Your FREE Sample Copy with Table of content@ https://www.emergenresearch.com/request-sample-form/83

However, ethical concerns regarding embryonic stem cells and less developed research infrastructure will hinder the stem cell therapy market's growth.

Companies Profiled in Stem Cell Therapy Market Research Report:

Virgin Health Bank, Celgene Corporation, ReNeuron Group plc, Biovault Family, Precious Cells International Ltd., Mesoblast Ltd., Opexa Therapeutics, Inc., Caladrius, Neuralstem, Inc., and Pluristem.

Key Highlights of Report

Check Our Prices@ https://www.emergenresearch.com/select-license/83Emergen Research has segmented the global stem cell therapy market in terms of type, application, end-users, and region:

Click to access the Report Study, Read key highlights of the Report and Look at Projected Trends: https://www.emergenresearch.com/industry-report/stem-cell-therapy-market

Take a Look at our Related Reports:

AI-Enabled Medical Imaging Solutions Market By Product (Software, Hardware), By Workflow (Image Acquisition, Image Analysis, Reporting, and Communication), By Therapeutic Application (General Imaging, Specialty Imaging), By Deployment Mode, By Modality, and By Region, Forecasts to 2027

Patient Registry Software Market By Delivery, By Database, By Registry Type, By Function, By Software Type (Integrated, Standalone), By End-use (Government & Third-Party Administrators, Pharmaceutical Companies, Hospitals, Research Centers, Others), and By Region, Forecast to 2027

Operating Room Management Solutions Market By Solution Type (Data management and communication solutions, Operating room supply management solutions, Anesthesia information management solutions, Operating room scheduling solutions, Performance management solutions), By Mode of Deployment (Ob-premises, Cloud-based), By End-Use (Hospitals, Ambulatory surgical centers), and By Region

About Emergen Research

Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Contact Us:

Eric Lee

Corporate Sales Specialist

Emergen Research | Web: http://www.emergenresearch.com

Direct Line: +1 (604) 757-9756

E-mail: sales@emergenresearch.com

Facebook | LinkedIn | Twitter | Blogs

Read Full Press Release@ https://www.emergenresearch.com/press-release/global-stem-cell-therapy-market

Continue reading here:

Stem Cell Therapy Market Size to Reach USD 5,040 Million by 2028 | Rising Public-Private Investments and Developing Regulatory Framework for Stem Cell...

SAN DIEGO (PRWEB) January 29, 2021

ProgenCell Stem Cell Therapies announced an updated stem cell therapy for anti aging or healthy aging protocol. A Comprehensive protocol developed by the more than 12 years of experience in the field of Regenerative Medicine and the most rigorous scientific protocols, and overseen by an Independent Review Board (IRB) composed by prominent figures in medicine and scientific research.

The Anti Aging Stem Cell Treatment Protocol is performed administering stem cells intravenously with a previous and strict regimen of multivitamins, minerals and hormones and a subsequent nutritional and vitamin support.

This updated protocol has been developed thanks to the information we have been able to compile, analyze and research, allowing us to determine the dosage of the vitamins. Hormones and nutrients administered according to each patients context, added Dr. Jorge Luis Gavio ProgenCells Medical Director. ProgenCells stem cell research center has an in-house laboratory and adjacent medical facility, which not only sets us apart as an institution, it also gives us the scientific platform to upgrade our protocols, he continued.

To date, ProgenCell Stem Cell Therapies has been offering stem cell therapy in Mexico successfully with a wide range of protocolos designed specifically for many conditions including Parkinsons Disease, Multiple Sclerosis, Retinitis Pigmentosa, and arthritis just to name a few.

Stem cell therapy for anti aging at ProgenCell Stem Cell Therapies is offered by board certified and fully licensed doctors, and every case is overseed by an Independent Review Board, with a scientific and Ethics Committee.

The treatments at ProgenCell Stem Cells comply with quality assurance standards that exceed those recommended by the FDA (Federal Drug Administration), and all protocols are registered and audited by COFEPRIS (the mexican government agency with jurisdiction).

The process of becoming a ProgenCell Patient for Anti Aging Stem Cell Therapy Protocol starts with a free virtual consultation with a Regenerative Medicine Scientific Liaison who will guide you through the process and establish a health route map. After the treatment is booked, a patient concierge works with each international patient on travel logistics, to live the full ProgenCel Experience.

For more information on stem cell therapy for anti aging and to obtain a free consultation, call (888) 443-6235 or visit http://www.progencell.com to learn more.

Share article on social media or email:

Continued here:

ProgenCell - Stem Cell Therapies offers an updated Stem Cell Therapy for Anti Aging Protocol - PR Web

Stem Cell Therapy Market is valued at USD 9.32 Billion in 2018 and expected to reach USD 16.51 Billion by 2025 with the CAGR of 8.5% over the forecast period.

Rising prevalence of chronic diseases, increasing spend on research & development and increasing collaboration between industry and academia driving the growth of stem cell therapy market.

Scope of Stem Cell Therapy Market-

Stem cells therapy also known as regenerative medicine therapy, stem-cell therapy is the use of stem cells to prevent or treat the condition or disease. Stem cell are the special type of cells those differentiated from other type of cell into two defining characteristics including the ability to differentiate into a specialized adult cell type and perpetual self-renewal. Under the appropriate conditions in the body or a laboratory stem cells are capable to build every tissue called daughter cells in the human body; hence these cells have great potential for future therapeutic uses in tissue regeneration and repair. Among stem cell pluripotent are the type of cell that can become any cell in the adult body, and multipotent type of cell are restricted to becoming a more limited population of cells.

Get Sample of This Report@ https://brandessenceresearch.com/requestSample/PostId/1246

The stem cell therapy has been used to treat people with conditions including leukemia and lymphoma, however this is the only form of stem-cell therapy which is widely practiced. Prochymal are another stem-cell therapy was conditionally approved in Canada in 2012 for the treatment of acute graft-vs-host disease in children those are not responding to steroids. Nevertheless, hematopoietic stem cell transplantation is the only established therapy using stem cells. This therapy involves the bone marrow transplantation.

Stem cell therapy market report is segmented based on type, therapeutic application, cell source and by regional & country level. Based upon type, stem cell therapy market is classified into allogeneic stem cell therapy market and autologous market.

Stem Cell Therapy Companies:

Stem cell therapy market report covers prominent players like,

Based upon therapeutic application, stem cell therapy market is classified into musculoskeletal disorders, wounds and injuries, cardiovascular diseases, surgeries, gastrointestinal diseases and other applications. Based upon cell source, stem cell therapy market is classified into adipose tissue-derived mesenchymal stem cells, bone marrow-derived mesenchymal stem cells, cord blood/embryonic stem cells and other cell sources

The regions covered in this stem cell therapy market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, market of stem cell therapy is sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.

Stem Cell Therapy Market Segmentation

By Type

Allogeneic Stem Cell Therapy Market, By Application

Autologous Market, By Application

By Therapeutic Application

By Cell Source

Stem Cell Therapy Market Dynamics

Rising spend on research and development activities in the research institutes and biotech industries driving the growth of the stem cell therapy market during the forecast period. For instance, in January 2010, U. S. based Augusta University initiated Phase I clinical trial to evaluate the safety and effectiveness of a single, autologous cord blood stem infusion for treatment of cerebral palsy in children. The study is estimated to complete in July 2020. Additionally, increasing prevalence of chronic diseases creating the demand of stem cell therapy. For instance, as per the international diabetes federation, in 2019, around 463 million population across the world were living with diabetes; by 2045 it is expected to rise around 700 million. Among all 79% of population with diabetes were living in low- and middle-income countries. These all factors are fuelling the growth of market over the forecast period. On the other flip, probabilities of getting success is less in the therapeutics by stem cell may restrain the growth of market. Nevertheless, Advancement of technologies and government initiative to encourage research in stem cell therapy expected to create lucrative opportunity in stem cell therapy market over the forecast period.

Stem Cell Therapy Market Regional Analysis

North America is dominating the stem cell therapy market due increasing adoption rate of novel stem cell therapies fueling the growth of market in the region. Additionally, favorable government initiatives have encouraging the regional market growth. For instance, government of Canada has initiated Strategic Innovation Fund Program, in which gov will invests in research activities carried out for stem cell therapies. In addition, good reimbursing scheme in the region helping patient to spend more on health. Above mentioned factors are expected to drive the North America over the forecast period.

Full Research Report @ https://brandessenceresearch.com/healthcare/stem-cell-therapy-market-size

About us: Brandessence Market Research and Consulting Pvt. Ltd.

Brandessence market research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals, and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations, and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London.

Contact usat: +44-2038074155 ormail usatsales@brandessenceresearch.com

Website: https://brandessenceresearch.com/

Article: https://businessstatsnews.com

Blog: https://technologyindustrynews.com

Blog: https://marketstatsreport.com

Blog: https://industrywatchnews.com/

Continued here:

Stem Cell Therapy Market 2021: Global Key Players, Trends, Share, Industry Size, Segmentation, Forecast To 2027 KSU | The Sentinel Newspaper - KSU |...